

Alpha-1 antitrypsin fact sheet for Primary Care

What is Alpha-1 antitrypsin?

Alpha-1 antitrypsin (AAT) is a protease inhibitor produced in the liver and transported to the lungs where it may also be produced locally by macrophages and bronchial epithelial cells. AAT protects the respiratory tract from enzymes released from white cells as part of normal immune function.

What is Alpha-1 antitrypsin deficiency?

Individuals with AAT deficiency have lower effective concentrations of AAT in their blood. Genetic changes (polymorphisms) can produce AAT that does not work properly (dysfunctional allele), AAT that is produced but becomes trapped or degraded intracellularly (deficiency alleles), or rarely a complete absence of AAT protein (null allele). Some polymorphisms can result in AAT that is both deficient and dysfunctional.

The effects of AATD are varied and, at least in part, depend on the type of polymorphism(s) present in an individual. Some people will suffer no ill effects whatsoever. The common clinical consequence of AAT deficiency is an increased risk of emphysema due to cumulative damage to the lungs by neutrophil elastases. Some patients may be at increased risk of liver disease including cirrhosis.

How common is AAT deficiency?

Approximately 1 in 3000 people in the UK have AAT deficiency; around 1 in 25 northern Europeans are carriers for AAT deficiency.¹

How is AAT deficiency diagnosed?

The concentration of AAT can be directly measured in blood (serum sample). If it is found to be low (<1.1 g/L) then the lab will go on to do phenotyping studies to establish whether there is a deficiency allele present. AAT levels > 0.8 g/L in the absence of inflammation are considered unlikely to be associated with significant lung disease.²

Occasionally, a low concentration of AAT may be picked up when serum electrophoresis is requested due to a reduced alpha zone. Direct measurement of AAT and phenotyping may then be performed to confirm this finding.

It should be noted that AAT is an acute phase reactant and therefore even patients with AAT deficiency may have normal or high levels of AAT during acute infection/inflammation. If acute infection or inflammation is suspected then a CRP should be requested at the same time. If CRP is raised then AAT should be repeated when the patient is well.

When should AAT be requested in primary care?

AAT is part of the non-invasive liver screen. Various guidelines also recommend quantitative AAT measurement in several scenarios including all adults with COPD, adult-onset asthma,

bronchiectasis of unknown aetiology (especially when co-existing with panacinar emphysema), or where there is a strong family history of lung or liver disease^{3, 4, 5}

What do the phenotyping results mean?

There are > 100 AAT variants, however, only a handful have the potential to cause AAT deficiency. The two most common AAT deficiency alleles are S and Z; the normal AAT allele is known as M. Individuals with the S allele have ~ 80% of normal circulating AAT due to intracellular degradation. This level of AAT is usually sufficient to protect the lungs but additional stressors e.g. smoking or environmental factors may increase the risk of emphysema in homozygotes. Patients with one S allele and one normal M allele generally have enough circulating AAT to provide adequate protection to the lungs.

The Z allele causes AAT to become trapped in the hepatocytes resulting in circulating levels ~15% of normal, however, AAT that does reach the circulation is dysfunctional and less effective. Patients with two copies of the Z allele are at risk of early onset emphysema due to inadequate protection for the lungs. In addition, AAT trapped in the hepatocytes directly causes liver injury which may range from mild hepatitis to cirrhosis requiring transplant. Individuals with one Z allele and one normal M allele are at a slightly increased risk of emphysema or liver disease, particularly in the presence of additional stressors e.g. smoking or increased alcohol. Individuals with one S allele and one Z allele have a moderate risk of emphysema and a slight increased risk of liver disease.

Normal AAT phenotypes are reported as M* rather than MM as it is not possible to exclude the presence of a null allele. However, this would be a very rare occurrence and would usually be associated with a much lower than expected AAT concentration. Individuals with a null allele are not at risk of liver disease.⁶

Table 1: 95% ranges of alpha-1 antitrypsin for adult phenotype groups. Adapted from Donato et al. and Ferrarotti et al.^{6,7} *It should be noted that AAT is an acute phase reactant and therefore levels may be higher than expected during acute infection/inflammation regardless of phenotype.

Phenotype	[AAT] 95% Range (g/L)*	Risk of Emphysema	Risk of liver disease
M/M	1.0-2.73	No increased risk	No increased risk
M/S	0.84-2.25	No increased risk	No increased risk
M/Z	0.61-1.56	Slight increased risk	Slight increased risk
M/Null	0.47 – 1.3	Possible slight increased risk	No increased risk
S/S	0.49-1.81	Possible slight increased risk	No increased risk
S/Z	0.42-1.08	Moderate risk (20-50%)	Slight increased risk
Z/Z	0.15-0.57	High risk (80-100%)	High risk
Null	0	High risk	No increased risk

What advice should be given to patients with AAT deficiency?

Individuals with existing emphysema or liver disease identified as having a deficiency allele should be offered a referral to a specialist for advice and management as should those with a ZZ or SZ phenotype.

Title of Document: Alpha-1 antitrypsin fact sheet for primary care

Q Pulse Reference No: BS/CB/DCB/PROTOCOLS/45

Authoriser: Peter Beresford

Version No: 3

All patients with a AAT deficiency (homozygotes) should be advised to avoid smoking and dust particles or chemicals that could irritate the lungs. Those with a Z type deficiency (or SZ) should also be advised to moderate alcohol consumption as this may increase the risk of developing liver disease.

Carriers of AAT deficiency alleles are unlikely to develop serious health problems but it is advisable to avoid cigarette smoke as carriers may be slightly more likely to develop lung problems if exposed to smoke. Carriers of AAT deficiency alleles who have never smoked appear to have the same risk of developing COPD as the general population.

It should be assumed that smoking of non-tobacco products or vaping carries the same risk of developing COPD as cigarette smoking.²

Should family members be tested?

There are currently no UK guidelines regarding family studies for patients with AAT deficiency. However, a European Respiratory Society statement recommended that siblings and partners of individuals with AAT deficiency should be offered phenotyping. Testing of parents may be considered where the presence of a null variant is suspected.⁸

The chances of an individual passing on carrier status or AAT deficiency to their children are shown in the table below.

	Partner Normal	Partner Carrier
Patient with AAT deficiency	All children will be carriers. No children will have AAT deficiency.	For each child there is a 1 in 2 chance that they will be a carrier or have AAT deficiency.
Patient Carrier	For each child there is a 1 in 2 chance that they will be a carrier. No children will have AAT deficiency.	For each child there is a 1 in 2 chance that they will be a carrier. For each child there is a 1 in 4 chance that they will have AAT deficiency.

References

1. Blanco et al. Estimated numbers and prevalence of PI*S and PI*Z alleles of a1-antitrypsin deficiency in European countries. *Eur Respir J* 2006; 27: 77–84
2. Hogarth DK. Alpha-1 antitrypsin deficiency. *BMJ Best Practice*. Mar 2021. <https://bestpractice.bmj.com/topics/en-gb/1075/pdf/1075/Alpha-1%20antitrypsin%20deficiency.pdf>. Last accessed 08 November 2021.
3. World Health Organization. Alpha-1 antitrypsin deficiency: memorandum from a WHO meeting. *Bull World Health Organ*. 1997;75:397-415
4. American Thoracic Society/European Respiratory Society Statement. Standards for the diagnosis and management of individuals with alpha 1-antitrypsin deficiency. *Am J Respir Crit Care Med*. 2003 Oct 1;168(7):818-900.
5. Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society Guideline for bronchiectasis in adults. *Thorax*. 2019 Jan;74(suppl 1):1-69

**BLOOD SCIENCES
DEPARTMENT OF CLINICAL BIOCHEMISTRY**



North Bristol
NHS Trust

Title of Document: Alpha-1 antitrypsin fact sheet for primary care

Q Pulse Reference No: BS/CB/DCB/PROTOCOLS/45

Authoriser: Peter Beresford

Version No: 3

6. Ferrarotti I, Carroll TP, Ottaviani S, et al. Identification and characterisation of eight novel SERPINA1 Null mutations. *Orphanet J Rare Dis.* 2014;9:172.
7. Donato et al., Reference and Interpretive Ranges for α 1-Antitrypsin Quantitation by Phenotype in Adult and Pediatric Populations. *Am J Clin Pathol* 2012;138:398-405
8. Miravittles M, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α 1-antitrypsin deficiency. *Eur Respir J.* 2017 Nov;50(5)